Agero Anna Liza C, Dusza Stephen W, Benvenuto-Andrade Cristiane, Busam Klaus J, Myskowski Patricia, Halpern Allan C
Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Am Acad Dermatol. 2006 Oct;55(4):657-70. doi: 10.1016/j.jaad.2005.10.010.
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for patients with colorectal and non-small cell lung cancer refractory or intolerant to chemotherapy. Our aim was to describe key clinical features of common dermatologic adverse reactions among EGFR inhibitors, focusing mainly on skin toxicity, as well as to discuss the pathology, possible causes, and suggested treatments for these reactions. The most commonly encountered adverse effect was a mild skin toxicity characterized by a sterile follicular and pustular rash that may be treated empirically and usually does not require treatment modification. Although the precise mechanism for development of rash is not well defined, it is related to inhibition of EGFR-signaling pathways in the skin, and may serve as visible markers of anti-tumor activity and therapeutic efficacy. Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis.
表皮生长因子受体（EGFR）抑制剂与独特且显著的皮肤副作用相关。西妥昔单抗、厄洛替尼和吉非替尼已被批准用于对化疗难治或不耐受的结直肠癌和非小细胞肺癌患者。我们的目的是描述EGFR抑制剂常见皮肤不良反应的关键临床特征，主要关注皮肤毒性，并讨论这些反应的病理、可能原因及建议的治疗方法。最常见的不良反应是一种轻度皮肤毒性，其特征为无菌性毛囊性和脓疱性皮疹，可凭经验治疗，通常无需调整治疗方案。尽管皮疹发生的确切机制尚不清楚，但它与皮肤中EGFR信号通路的抑制有关，并且可能作为抗肿瘤活性和治疗效果的可见标志物。抗EGFR治疗中出现的次要不良反应包括皮肤干燥、瘙痒、甲沟炎、毛发异常和黏膜炎。
